China's first original anti AI new drug iconine ® is on the market

On September 2, 2018, the global launch conference of the world's first long-acting HIV-1 fusion inhibitor, ibovetai (aikonin ®), developed by China's innovative biomedical enterprise frontier biopharmaceutical (Nanjing) Co., Ltd., was held in Nanjing, attended by nearly 200 clinical experts and scholars in the field of anti infection At the launch ceremony, iconine ® is a human immunodeficiency virus (HIV-1) fusion inhibitor, which is suitable for use in combination with other antiretroviral drugs to treat HIV-1 infected people who still have HIV-1 replication after treatment with other antiretroviral drugs Iconine ® is the first long-acting HIV-1 fusion inhibitor in the world and the first original anti HIV drug in China It is independently developed by cutting-edge biology and has global intellectual property rights Aikonin ® has a new molecular mechanism of action, which is effective for HIV-1 virus and drug-resistant virus, and has the unique advantages of low drug frequency (once a week), high drug resistance barrier and high safety "Cutting edge biology is committed to the development of new drugs that can meet major clinical needs, cure diseases and save people, and improve the quality of human life Iconine ® is the first independent innovative drug in the field of AIDS in China, providing new treatment options for the majority of HIV infected people Its long-term injection formula is an important supplement and improvement of the current oral drug treatment program We look forward to "zero breakthrough" in the field of new AIDS drugs, which can truly benefit patients and save lives " Xie Dong, chairman and chief scientist of Frontier biology, said AIDS prevention and control is facing severe challenges AIDS is a major infectious disease in the field of public health, mainly through sexual transmission HIV mainly attacks the human immune system, taking the most important CD4T lymphocytes in the human immune system as the first target of attack, damaging immune cells in a large area, making the human body lose its immune function to the outside world, easily infecting various diseases, including malignant tumors, leading to a high mortality rate of AIDS From 2010 to 2017, the number of AIDS cases and deaths in China has been on the rise According to the statistical communique on the development of health services issued by the national health and Health Commission, in 2017, the number of AIDS patients was 57194, and the number of deaths was 15251, ranking first in class A and class B infectious diseases in China By July 31, 2017, 728270 people living with HIV / AIDS had been reported nationwide For a long time, China's AIDS treatment drugs are imported drugs or generic drugs, there is no independent research and development of new anti AIDS drugs, the demand for clinical treatment of new anti AIDS drugs is growing rapidly, so that Chinese patients can use the independently developed new anti AIDS drugs and good drugs has been the dream of the pharmaceutical industry "As the first class a new anti AIDS drug originally developed in China, and the first long-acting HIV-1 fusion inhibitor in the world, iconine ® is listed in China, which represents the new level of anti AIDS drug research and development in China Iconine ® has a better therapeutic effect on drug-resistant patients with treatment failure, and its side effects are smaller than those of other types of drugs Therefore, a new treatment option is added for patients with treatment failure and intolerable side effects due to other types of drugs, which will also enable AIDS patients in our country to receive better medical treatment Because of the new mechanism of action of iconine, it is expected to carry out early intervention and prevention for some exposed people in the future " Professor Li Taisheng, chairman of the infectious diseases branch of the Chinese Medical Association and director of the infection department of the Union Hospital, said Long acting drugs have created a new era of AIDS treatment At present, there are more than 30 anti AIDS drugs and multiple compound preparations on the market in the world, only one long acting injection drug Long term use of many drugs in patients, some will inevitably produce drug resistance, which not only endangers the life and health of patients, but also may cause the spread of drug-resistant virus "The success of the R & D of iconine ® is the great achievement of the creation of major new drugs, the crystallization of the wisdom of scientific researchers, and the model of the cooperation between Chinese pharmaceutical R & D and clinical medicine After its launch, iconine ® has filled several gaps in antiviral drugs in China: first, it is the first long-acting HIV fusion inhibitor in the world, opening the era of long-acting antiviral drugs in China; second, the new mechanism of action of iconine ® is effective for known drug-resistant viruses, complementary to existing drug mechanisms, and can save the lives of patients; third, as a peptide drug for injection The side effects of iconine are small, the safety is high, it is not affected by oral and gastrointestinal function, and it can meet some urgent clinical medication needs Professor Wu Hao, director of the infection center of Beijing You'an Hospital Affiliated to Capital Medical University, who is the principal investigator of the clinical trial of aikoning, said Fill in the blank of new anti AI drugs, provide new choice and new hope for the clinical trial results of aikonin ® show that the efficacy of the combination of aikonin ® and antiretroviral drugs is equivalent to or better than the standard drug combination recommended by the World Health Organization, and the renal safety is significantly better than that of the control group For AIDS antiviral treatment to provide a more optimized treatment plan, more drug choice, for drug-resistant patients at home and abroad, surgery and inpatients to provide a new choice of treatment, new hope for life The successful R & D and listing of iconine ® not only fills the gap in the field of anti AIDS drug R & D in China, improves the overall level of independent R & D in China, but also creates a new situation of long-term anti AIDS drug treatment, leads the international treatment trend, and embodies the original strength of China Frontier biology: Tongxin Zhiyuan, founded in 2002 by senior returnees, is an innovative biopharmaceutical enterprise based in China and facing the global market Focus on R & D, production and sales of new drug products to meet major clinical needs, cure and save people, and improve the quality of human life Innovation and scientific research is the leading edge of cutting-edge biology, and the company's core team has rich experience in the successful development of new drugs at home and abroad At this stage, we focus on the R & D and promotion of innovative drugs in the important fields of AIDS antiviral treatment and pain After more than ten years of honing and accumulation, frontier biology has owned a long-term peptide drug research and development platform with global intellectual property rights and a number of products under research Frontier biology is willing to make long-term and great efforts to provide innovative drugs and services for patients, and make positive contributions to the common social development goal of human beings, which is to treat major diseases, improve health level and improve quality of life.